ストックスクリーナーアプリを入手
67.55
0.22%
0.145
アフターアワーズ：
67.55
前日終値:
$67.41
開ける：
$67.58
24時間の取引高:
2.54M
Relative Volume:
1.01
時価総額：
$13.23B
収益：
$579.96M
当期純損益:
$-729.89M
株価収益率:
-18.03
EPS:
-3.7459
ネットキャッシュフロー:
$-452.02M
1週間 パフォーマンス:
+0.33%
1か月 パフォーマンス:
+4.44%
6か月 パフォーマンス:
-8.80%
1年 パフォーマンス:
+72.98%
1日の値動き範囲:
$66.78
$69.03
1週間の範囲:
$65.83
$69.51
52週間の値動き範囲:
$38.57
$84.94
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Compare BBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
67.55 | 13.20B | 579.96M | -729.89M | -452.02M | -3.7459 |
VRTX
Vertex Pharmaceuticals Inc
|
445.04 | 110.59B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
611.48 | 63.08B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
898.94 | 53.62B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
289.39 | 38.88B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 30.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-09 | 開始されました | RBC Capital Mkts | Outperform |
| 2026-03-10 | 開始されました | William Blair | Outperform |
| 2026-01-28 | 開始されました | Barclays | Overweight |
| 2026-01-06 | 開始されました | Morgan Stanley | Overweight |
| 2025-12-11 | 開始されました | Bernstein | Outperform |
| 2025-07-30 | 再開されました | Raymond James | Outperform |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-07-14 | 開始されました | Jefferies | Buy |
| 2025-07-09 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-06-17 | 開始されました | Wolfe Research | Outperform |
| 2025-03-31 | 開始されました | Redburn Atlantic | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-10-03 | 開始されました | Oppenheimer | Perform |
| 2024-09-04 | 開始されました | Piper Sandler | Overweight |
| 2024-03-21 | 再開されました | Raymond James | Outperform |
| 2024-01-31 | 開始されました | BMO Capital Markets | Market Perform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-11-07 | 開始されました | Citigroup | Buy |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-07-18 | ダウングレード | Jefferies | Buy → Hold |
| 2023-04-19 | 開始されました | Evercore ISI | Outperform |
| 2023-02-06 | 開始されました | Cowen | Outperform |
| 2021-12-27 | 繰り返されました | Mizuho | Buy |
| 2021-12-27 | 繰り返されました | SVB Leerink | Outperform |
| 2021-09-10 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-03-22 | 繰り返されました | Goldman | Buy |
| 2021-02-22 | 再開されました | JP Morgan | Overweight |
| 2021-02-09 | 再開されました | Goldman | Buy |
| 2021-01-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-25 | 開始されました | BofA/Merrill | Neutral |
| 2020-05-19 | 開始されました | BTIG Research | Buy |
| 2020-04-13 | 開始されました | H.C. Wainwright | Buy |
| 2020-02-19 | 開始されました | Mizuho | Buy |
| 2019-07-26 | 開始されました | Raymond James | Outperform |
| 2019-07-22 | 開始されました | BMO Capital Markets | Outperform |
| 2019-07-22 | 開始されました | Goldman | Buy |
| 2019-07-22 | 開始されました | JP Morgan | Overweight |
| 2019-07-22 | 開始されました | Jefferies | Buy |
| 2019-07-22 | 開始されました | Piper Jaffray | Overweight |
| 2019-07-22 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Bridgebio Pharma Inc (BBIO) 最新ニュース
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma, Inc. $BBIO Shares Acquired by GW&K Investment Management LLC - MarketBeat
BridgeBio Pharma, Inc. $BBIO Position Lifted by Franklin Resources Inc. - MarketBeat
Raymond James downgrades BridgeBio Pharma (BBIO) - MSN
BridgeBio Pharma Insider Sold Shares Worth $5,413,289, According to a Recent SEC Filing - marketscreener.com
BridgeBio Pharma(BBIO.US) Officer Sells US$5.41 Million in Common Stock - Moomoo
BridgeBio Pharma CEO Neil Kumar sells $5.4m in company stock - Investing.com
BridgeBio Pharma (BBIO) CEO’s family trusts sell 80,000 shares under 10b5-1 plan - Stock Titan
Mizuho reiterates Outperform on BridgeBio stock on Russell move By Investing.com - Investing.com Canada
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Uncovering a Potential 51.92% Upside in the Biotechnology Sector - DirectorsTalk Interviews
Operating income of BridgeBio Pharma, Inc. – XETR:2CL - TradingView
Return on assets % of BridgeBio Pharma, Inc. – XETR:2CL - TradingView
Gross profit of BridgeBio Pharma, Inc. – XETR:2CL - TradingView
ETFs Investing in BridgeBio Pharma, Inc. Stocks - TradingView
BridgeBio Pharma, Inc. Balance Sheet – XETR:2CL - TradingView
BridgeBio Pharma, Inc. Cash Flow – XETR:2CL - TradingView
Biotech BridgeBio hands new recruits 31,428 stock units - Stock Titan
Brazil approves BridgeBio’s acoramidis for heart condition - Investing.com
Barclays Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $157 - Moomoo
BBIO: Attruby’s rapid growth and differentiated data anchor a pipeline poised for multiple rare disease launches - TradingView
BBIO: Attruby's rapid growth and differentiated data drive momentum as multiple rare disease launches near - TradingView
symbol__ Stock Quote Price and Forecast - CNN
BridgeBio (BBIO) Receives Buy Rating with $104 Target by Canacco - GuruFocus
CCORF Initiates BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $104 - Moomoo
Canaccord Genuity Group Initiates Coverage on BridgeBio Pharma (NASDAQ:BBIO) - MarketBeat
Precision Trading with Bridgebio Pharma Inc. (BBIO) Risk Zones - Stock Traders Daily
BridgeBio Pharma director Ellis Andrea sells $4.2m in shares - Investing.com
Citi Maintains BridgeBio Pharma(BBIO.US) With Hold Rating, Maintains Target Price $82 - Moomoo
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Exploring a Promising 54.93% Upside Potential - DirectorsTalk Interviews
Does FDA Priority Review for First LGMD Therapy Change The Bull Case For BridgeBio Pharma (BBIO)? - Yahoo Finance
BridgeBio gains as muscular dystrophy therapy gets FDA priority review - MSN
Farallon funds hold multi‑million share positions in BridgeBio (NASDAQ: BBIO) - Stock Titan
BBIO Maintained by Morgan Stanley -- Price Target Raised to $98. - GuruFocus
BBIO Maintained by Morgan Stanley -- Price Target Raised to $98.00 - GuruFocus
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $110 - Moomoo
BBIO Reiterates by HC Wainwright & Co. -- Price Target Maintained at $110 - GuruFocus
FDA accepts BridgeBio’s BBP-418 for priority review - The Pharma Letter
BridgeBio (BBIO) Secures FDA Filing Acceptance for BBP-418 - GuruFocus
FDA grants Priority Review to BridgeBio (NASDAQ: BBIO) BBP-418 NDA - Stock Titan
BridgeBio Pharma (BBIO) Shares Rise on FDA Priority Review for B - GuruFocus
BridgeBio Pharma (BBIO) Shares Rise on FDA Priority Review for BBP-418 - GuruFocus
BridgeBio gains FDA review for muscle disorder drug (BBIO) - Seeking Alpha
BridgeBio’s LGMD2I/R9 drug receives FDA priority review By Investing.com - Investing.com Nigeria
BridgeBio Pharma Announces FDA Acceptance of BBP-418 NDA for Limb-Girdle Muscular Dystrophy Type 2I/R9 with Priority Review Status - Quiver Quantitative
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9 - The Manila Times
BridgeBio’s LGMD2I/R9 drug receives FDA priority review - Investing.com
FDA priority review for first potential LGMD2I/R9 treatment - Stock Titan
BridgeBio Pharma Shares Fall After Raymond James Downgrade - Moomoo
Bridgebio Pharma Insider Sold Shares Worth $1,812,522, According to a Recent SEC Filing - Moomoo
BridgeBio (BBIO) CEO Neil Kumar sells 26,103 shares in Rule 10b5-1 trades - Stock Titan
BBIO Downgraded by Raymond James -- Rating Changed to Market Per - GuruFocus
Bridgebio Pharma Inc (BBIO) 財務データ
収益
当期純利益
現金流量
EPS
4.65%
1.27%
大文字化:
|
ボリューム (24 時間):